DE60016567D1 - Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode - Google Patents

Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode

Info

Publication number
DE60016567D1
DE60016567D1 DE2000616567 DE60016567T DE60016567D1 DE 60016567 D1 DE60016567 D1 DE 60016567D1 DE 2000616567 DE2000616567 DE 2000616567 DE 60016567 T DE60016567 T DE 60016567T DE 60016567 D1 DE60016567 D1 DE 60016567D1
Authority
DE
Germany
Prior art keywords
infectious
macrophage
preparation
based composition
hematopoietic properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE2000616567
Other languages
English (en)
Other versions
DE60016567T2 (de
Inventor
Bernard Klein
Yang Lu
Jacques Bartholeyns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IDM Immuno Designed Molecules
Centre Hospitalier Universitaire de Montpellier CHUM
Original Assignee
IDM Immuno Designed Molecules
Centre Hospitalier Universitaire de Montpellier CHUM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IDM Immuno Designed Molecules, Centre Hospitalier Universitaire de Montpellier CHUM filed Critical IDM Immuno Designed Molecules
Publication of DE60016567D1 publication Critical patent/DE60016567D1/de
Application granted granted Critical
Publication of DE60016567T2 publication Critical patent/DE60016567T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60016567T 1999-02-03 2000-01-27 Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode Expired - Fee Related DE60016567T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99400239 1999-02-03
EP99400239 1999-02-03
PCT/EP2000/000647 WO2000045827A1 (en) 1999-02-03 2000-01-27 Cell composition containing macrophages, presenting anti-infectious and hematopoietic properties, and a process for preparing the same

Publications (2)

Publication Number Publication Date
DE60016567D1 true DE60016567D1 (de) 2005-01-13
DE60016567T2 DE60016567T2 (de) 2005-12-08

Family

ID=8241869

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60016567T Expired - Fee Related DE60016567T2 (de) 1999-02-03 2000-01-27 Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode

Country Status (8)

Country Link
US (1) US6737051B1 (de)
EP (1) EP1150694B1 (de)
AT (1) ATE284220T1 (de)
AU (1) AU782937B2 (de)
CA (1) CA2361608A1 (de)
DE (1) DE60016567T2 (de)
ES (1) ES2233327T3 (de)
WO (1) WO2000045827A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044300A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040077985A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
AU2003254363A1 (en) * 2003-07-16 2005-02-25 I.D.M. Immuno-Designed Molecules Compositions containing macrophages and uses thereof
US7508684B2 (en) * 2006-08-18 2009-03-24 Research In Motion Limited Handheld electronic device including multi-compartment shielding container and associated methods
WO2009086596A1 (en) * 2008-01-08 2009-07-16 The University Of Queensland Method of producing a population of cells
GB201608806D0 (en) * 2016-05-19 2016-07-06 Immodulon Therapeutics Ltd Method
AU2017301681A1 (en) * 2016-07-25 2019-03-07 Cellular Approaches, Inc. Autologous and allogenic macrophages and monocytes for use in therapeutic methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282725C (en) * 1986-04-18 1991-04-09 Brian A. Naughton Process for replicating bone marrow in vitro and using the same
US5649904A (en) * 1988-10-07 1997-07-22 Sandoz Ltd. Method of treating cancer with a fully myeloablative regimen of chemotherapy, radiation or both
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5672346A (en) * 1992-07-27 1997-09-30 Indiana University Foundation Human stem cell compositions and methods
US6060052A (en) * 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof

Also Published As

Publication number Publication date
ATE284220T1 (de) 2004-12-15
US6737051B1 (en) 2004-05-18
WO2000045827A1 (en) 2000-08-10
AU782937B2 (en) 2005-09-08
EP1150694A1 (de) 2001-11-07
ES2233327T3 (es) 2005-06-16
AU2293800A (en) 2000-08-25
DE60016567T2 (de) 2005-12-08
EP1150694B1 (de) 2004-12-08
CA2361608A1 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
TR200101793T2 (tr) CCR5 modülatörleri olarak azabisikloalkanlar
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
EA200500149A1 (ru) Тканевые протективные цитокины для защиты, восстановления и стимуляции реактивных клеток, тканей и органов
DE69636989D1 (de) Bioaktive lasttragende zusammensetzungen zum knochenverbund
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
SE9803986D0 (sv) New compositions
MY119403A (en) Novel compounds with analgesic effect.
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
ES2103587T3 (es) Composiciones terapeuticas ingeribles, estables y absorbibles de nadh y de nadph.
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
DE69932510D1 (de) Vaskularisierungsinhibitoren
ATE243196T1 (de) Piperidine und pyrrolidine
PL323364A1 (en) Bicyclic aromatic compounds
PL343375A1 (en) Matrix protein compositions for wound healing
GR3035576T3 (en) Diaromatic propynyl or dienyl compounds
DE60016567D1 (de) Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode
RS60604A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
DE60036725D1 (de) Zusammensetzungen enthaltend vernix und ein uv-schutzmittel, und deren verwendung
WO2004030623A3 (en) Nitroxide radioprotector formulations and methods of use
MXPA02011592A (es) Composiciones de celulas dendriticas circulantes, humanas y metodos.
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
ATE46360T1 (de) Plasminogenaktivator fuer menschliches gewebe, diesen aktivator enthaltende pharmazeutische zusammensetzungen, verfahren zur herstellung des aktivators sowie dna und transformierte zellzwischenprodukte hierfuer.
UA41154A (uk) Лікувальний засіб "гермогран-м" на основі олії з зародків пшениці

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee